

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 October 2024 (17.10.2024)



(10) International Publication Number
WO 2024/213640 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 16/18 (2006.01)
A61K 39/395 (2006.01) C07K 16/28 (2006.01)
A61K 47/68 (2017.01) A61K 35/12 (2015.01)
A61P 35/00 (2006.01) A61K 31/635 (2006.01)
C07K 14/78 (2006.01)

(21) International Application Number:

PCT/EP2024/059847

(22) International Filing Date:

11 April 2024 (11.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202301006Y	11 April 2023 (11.04.2023)	SG
10202302846W	05 October 2023 (05.10.2023)	SG
10202302916W	13 October 2023 (13.10.2023)	SG

(71) Applicants: **STERLING IP PTE. LTD.** [SG/SG]; 1 IRVING PLACE, #07-10 THE COMMERZE@IRVING, Singapore 369546 (SG). **STERLING IP** [GB/GB]; Orion House, Bessemer Road, Welwyn Garden City Hertfordshire AL7 1HH (GB).

(72) Inventors: **BEADLE, John**; Park Gate, Maidensgrove Oxfordshire RG9 6HA (GB). **MOORE, Andrew**; c/o Milner Therapeutics Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AW (GB). **RINGHAUSEN, Ingo**; c/o Milner Therapeutics Institute, Jeffrey Cheah Biomedical Centre, Cambridge Biomedical Campus, Cambridge Cambridgeshire CB2 0AW (GB). **HAMBLETON, Bernadette**; c/o Sterling IP Ltd, Orion House, Bessemer Road, Welwyn Garden City Hertfordshire AL7 1HH (GB).

(74) Agent: **STERLING IP**; Orion House, Bessemer Road, Welwyn Garden City Hertfordshire AL7 1HH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: INHIBITION OF: STROMA/CANCER CELL CROSS-TALK &/OR STROMA GENERATED RESISTANCE TO TREATMENT

(57) Abstract: The present disclosure relates to a method of treating aberrantly activated (or reactive) stroma, for example cancer stroma, to change the status thereof, for example to render it/them less permissive to cancer cells or other diseased cells/tissue and/or to reduce stroma generated resistance to treatment using an antibody or antigen binding fragment thereof that is an inhibitor of the FBG region of tenascin C.

WO 2024/213640 A1